Unicycive Therapeutics, Inc. (UNCY): Capital Expenditures
$24.0K
Year ended 2025-12-31
$9.0K
Trailing 12 months to 2026-06-30
+128.9%
3-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $24.0K | -66.7% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $72.0K | +500.0% | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | $12.0K | +500.0% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $2.0K | -93.1% | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | $29.0K | n/a | 2023-03-31, From 2021-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Unicycive Therapeutics, Inc. (UNCY) | 2025-12-31 | $24.0K | -66.7% |
| NextCure, Inc. (NXTC) | 2024-12-31 | $474.0K | -42.2% |
| Atossa Therapeutics, Inc. (ATOS) | 2025-12-31 | $23.0K | +21.1% |
| Verrica Pharmaceuticals Inc. (VRCA) | 2025-12-31 | $0 | -100.0% |
| Actinium Pharmaceuticals, Inc. (ATNM) | 2025-12-31 | $104.0K | +845.5% |
| Mereo BioPharma Group plc (MREO) | 2025-12-31 | $20.0K | n/a |
| Medicinova Inc (MNOV) | 2025-12-31 | $2.9K | +223.9% |
| Spruce Biosciences, Inc. (SPRB) | 2024-12-31 | $0 | -100.0% |
| BioXcel Therapeutics, Inc. (BTAIQ) | 2025-12-31 | $0 | n/a |
Compare UNCY, NXTC, ATOS, VRCA side by side · Screen every company in Pharmaceutical Preparations ↗